Breast Cancer: Diagnosis and Staging

Breast Cancer: Diagnosis and Staging

Breast Cancer: Diagnosis and Staging

On this page

Breast Cancer: Risks & Alerts - Spotting Trouble Early

  • Major Risk Factors:
    • Non-Modifiable:
      • Age (↑ risk >50 yrs), Female sex
      • Family Hx (1st degree), BRCA1/BRCA2 mutations
      • Personal Hx of breast Ca, LCIS, ADH
      • Early menarche (<12 yrs), Late menopause (>55 yrs)
      • Dense breast tissue
    • Modifiable:
      • Nulliparity or late first child (>30 yrs)
      • No breastfeeding
      • Combined HRT, OCPs (slight risk)
      • Obesity (postmenopausal), Alcohol, Radiation exposure
  • Clinical Alerts (Symptoms):
    • Painless lump (most common presentation)
    • Nipple changes: inversion/retraction, spontaneous bloody/serous discharge, Paget’s disease (eczematous changes)
    • Skin changes: dimpling (peau d’orange), tethering, erythema, ulceration
    • Axillary or supraclavicular lymphadenopathy
    • Breast asymmetry, contour changes, persistent pain (less common) Breast Cancer: Risk Factors, Progression, Treatment

⭐ Most common site of breast cancer: Upper Outer Quadrant (UOQ).

Breast Cancer: Detective Work - Confirming Suspicions

  • Screening Methods:
    • Mammography: Annually for women aged >40-45 years (guidelines vary).
    • Clinical Breast Exam (CBE): Part of routine check-ups.
    • Breast Self-Exam (BSE): Promotes awareness.
  • Diagnostic Pathway:

    ⭐ Triple Assessment (Clinical exam, Imaging, Pathology/Biopsy) is key for diagnosis of palpable breast lumps.

*   **Imaging Insights**:
    *   Mammography: Detects masses, architectural distortion, microcalcifications. BI-RADS score guides management.
    *   Ultrasound: Differentiates solid vs. cystic lesions; primary tool <**35** yrs; guides biopsy.
    *   MRI: High-risk screening; assesses extent, multifocality, response to neoadjuvant chemotherapy.
*   **Pathology Confirmation**:
    *   Core Needle Biopsy (CNB): **Gold standard** for diagnosis. Provides tissue for histology, grade, and receptor status (ER, PR, HER2).
    *   FNAC: Limited; cannot assess invasiveness.
  • Staging: Based on TNM classification (Tumor size, Nodal status, Metastasis).

Breast Cancer: Lab Deep Dive - Types & Traits

  • Histopathology (Biopsy):
    • Invasive Ductal Carcinoma (IDC) NOS: Most common (~75%). Gritty, stellate appearance.
    • Invasive Lobular Carcinoma (ILC): ~10-15%. "Indian file" pattern (single cells in rows), often multifocal/bilateral.
    • Others: Tubular, Mucinous (Colloid), Medullary, Papillary.
  • Key Receptors & Markers (IHC Panel):
    • Estrogen Receptor (ER)
    • Progesterone Receptor (PR)
    • HER2/neu (Human Epidermal growth factor Receptor 2)
    • Ki-67 (Proliferation index)
  • Molecular Subtypes (Prognostic & Predictive):
    • Luminal A: ER+/PR+, HER2-, Low Ki-67. Best prognosis.
    • Luminal B: ER+/PR+, HER2+ OR (HER2- & High Ki-67).
    • HER2 Enriched: ER-/PR-, HER2+.
    • Basal-like (TNBC): ER-/PR-, HER2-. Breast Cancer Subtypes and Prognosis

⭐ Triple-negative breast cancer (TNBC) - ER negative, PR negative, HER2 negative - generally has the poorest prognosis among common subtypes.

Breast Cancer: Staging Showdown - Sizing Up the Foe

  • TNM System (AJCC 8th Ed.): Key for prognosis & therapy.
    • T (Tumor Size):
      • Tis: In situ
      • T1: ≤ 2 cm (T1mi ≤ 0.1 cm; T1a >0.1-0.5 cm; T1b >0.5-1 cm; T1c >1-2 cm)
      • T2: > 2 cm - ≤ 5 cm
      • T3: > 5 cm
      • T4: Chest wall/skin invasion; inflammatory (T4d)
    • N (Nodes):
      • N0: No regional LN
      • N1: Mobile ipsilateral axillary
      • N2: Fixed axillary OR isolated internal mammary (clinically apparent)
      • N3: Infraclavicular/supraclavicular/internal mammary + axillary
    • M (Metastasis):
      • M0: No distant
      • M1: Distant
  • Staging Types: Clinical (cTNM), Pathological (pTNM).

⭐ Axillary lymph node status is the single most important prognostic factor in early-stage, operable breast cancer. Breast cancer biomarkers and treatment by stage

High‑Yield Points - ⚡ Biggest Takeaways

  • Triple assessment (clinical exam, imaging, pathology) is vital for diagnosis.
  • Mammography is key for screening (>40 yrs); USG for younger or dense breasts.
  • MRI aids high-risk screening, staging, and assessing NACT response.
  • Core needle biopsy is the gold standard for definitive histological diagnosis.
  • Staging uses the TNM system; pathological staging is most accurate.
  • ER, PR, and HER2/neu status are crucial for prognosis and guiding therapy.
  • Axillary lymph node status remains the single most important prognostic factor.
Rezzy AI Tutor

Have doubts about this lesson?

Ask Rezzy, our AI tutor, to explain anything you didn't understand

Practice Questions: Breast Cancer: Diagnosis and Staging

Test your understanding with these related questions

Fluorescence in situ hybridization (FISH) is required in which of the following interpretations of Her2/neu?

1 of 5

Flashcards: Breast Cancer: Diagnosis and Staging

1/10

According to the T category under AJCC classification of breast cancer, tumor size _____ mm is T3

TAP TO REVEAL ANSWER

According to the T category under AJCC classification of breast cancer, tumor size _____ mm is T3

>50

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start For Free
Breast Cancer: Diagnosis and Sta... - Free Indian Medical PG